- In September 2023, Cybin Inc. announced a strategic collaboration with Fluence, a leader in continuing education for psychedelic therapy. This partnership is aimed at supporting the expansion of the EMBARK training program for the CYB003 phase 3 trial
- In September 2023, Enveric Biosciences revealed that the psychedelic drug MDMA is closer to receiving FDA approval for the treatment of post-traumatic stress disorder (PTSD), following promising trial results in the U.S.
- In October 2022, Numinus Wellness Inc., a prominent mental health care provider, introduced its innovative Ketamine program aimed at treating chronic and severe medical conditions. The program was first implemented in Numinus' clinics in Utah, British Columbia, and Quebec, with plans for expansion to additional locations
- In March 2022, researchers at the University of California published follow-up data from a phase 3 clinical trial investigating the use of MDMA in combination with psychotherapy for PTSD treatment. The preliminary results indicated the therapy’s potential effectiveness, even in patients with co-occurring drug or alcohol use disorders
- In December 2021, HAVN Research Inc. exported psilocybin from Jamaica for investigational research purposes, aiming to explore its potential as an active pharmaceutical ingredient (API) to promote brain health in patients
